AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Intensity Therapeutics Plunges 46.46% on Public Offering
Generated by AI AgentAinvest Pre-Market Radar
Thursday, Jun 12, 2025 4:56 am ET1min read
On June 12, 2025,
, Inc. experienced a significant drop of 46.46% in pre-market trading, marking a substantial decline in its stock value.Intensity Therapeutics, Inc. has recently announced a proposed public offering of its common stock. The company plans to use the net proceeds from this offering to enroll patients and reach data readout in the INVINCIBLE-4 Study, which is a crucial phase in its clinical trials for cancer immunotherapy.
The public offering includes 6,675,000 shares priced at $0.30 per share. The company has also granted underwriters a 45-day option to purchase additional shares, indicating a strategic move to raise capital for its ongoing research and development efforts.
This public offering is part of
Therapeutics' broader strategy to secure funding for its innovative cancer immunotherapy platform. The company aims to leverage the capital raised to advance its clinical trials and bring its groundbreaking treatments closer to market.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
SEALSQ Surged 8.29% Driven by 2026–2030 Roadmap for Silicon-Based Quantum Computing Systems
Dec.19 2025
Serve Robotics (SERV) Surges 5.97% on Bullish Oppenheimer Note
Dec.19 2025
AXT Inc. shares surge 13.35% on renewed earnings upside speculation amid supply chain adjustments
Dec.19 2025
PROK surged 5.11% on Dec. 19 2025 after HC Wainwright upgraded to Buy rating
Dec.19 2025
Tesla shares surge 3.45% as SpaceX orders 1,000-2,000 Cybertrucks for Starbase facility.
Dec.19 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet